Who We Are

Association of Biotechnology Led Enterprises - ABLE is a not-for-profit pan-India forum that represents the Indian Biotechnology Sector. It was launched in April 2003, after industry leaders felt a need to form an exclusive forum to represent the Indian Biotechnology Sector.

ABLE has over 400 members from all across India representing all verticals of the sector like Agribiotech, Bio-pharma, Industrial biotech, Bioinformatics, Investment banks and Venture Capital firms, leading Research and Academic Institutes and Law Firms and Equipment Suppliers.

The primary focus of ABLE is to accelerate the pace of growth of the Biotechnology sector in India, through partnering with the Government in their biotechnology initiatives to deliver optimal policies and create a positive regulatory environment, encouraging entrepreneurship and investment in the sector, providing a platform for domestic and overseas companies to explore collaboration and partnerships, forging stronger links between academia and industry and showcasing the strengths of the Indian biotech sector.

ABLE thus catalyses a symbiotic interface between the industry, the government, academic and research institutes and domestic and international investors.

Executive Council

Ms. Kiran Mazumdar Shaw

Ms. Kiran Mazumdar Shaw

Hon. Non Executive Chairman ABLE

Chairman & Managing Director, Biocon

A successful technocrat of global standing, Ms. Shaw heads India's leading Biotechnology enterprise, Biocon. She is highly respected in the corporate world and has been recently voted by Nature Biotechnology as The Most Influential in Bio-business person outside Europe and USA.

Ms. Shaw received a graduate honours degree in Zoology from Bangalore University (1973) and qualified as a Master Brewer from Ballarat University, Australia (1975). Ms Shaw also received an honorary Doctorate of Science in 2004, from her alma mater, Ballarat University, in recognition of her pre-eminent contributions to the field of Biotechnology. She has also been awarded honarary doctorates from University of Abertay, Dundee, U.K. (2007), University of Glasgow, U.K. (2008) and Heriot-Watt University, Edinburgh, U.K. (2008).

Ms Shaw chairs Karnataka's Vision Group on Biotechnology and also served on the Board of Science Foundation, Ireland. She presently serves on the Advisory Council of the Government's Department of Biotechnology where she has been instrumental in bringing government, industry and academia together, to chart a clear and progressive growth path for Biotechnology in India. Most recently, she has been invited to join the Prime Minister's Council on Trade & Industry in India and the US-India CEO Forum.

Ms. Shaw is the recipient of several prestigious awards including the ET Businesswoman of the Year, Ernst & Young's Entrepreneur of the Year Award for Life Sciences & Healthcare, Technology Pioneer, etc. Her most cherished awards are the national awards, PADMASHRI (1989) and PADMA BHUSHAN (2005) presented to her by the President of India, for her pioneering efforts in Industrial Biotechnology.

Under her stewardship, Biocon has evolved from its inception in 1978 as an industrial enzymes company to a fully integrated Bio-pharmaceutical enterprise encompassing a well balanced business portfolio of products and services with a research focus on Diabetes, Oncology and Auto-immune disease. During this transition, Biocon has established 2 subsidiaries: Syngene (1994) to provide development support services for discovery research and Clinigene (2000) to cater to services in clinical development.

A leading US trade publication, Med Ad News, in its 2007 listings has ranked Biocon 20th amongst the leading biotechnology companies in the world and the 7th largest Biotech employer globally.

Dr. P.M. Murali

Dr. P.M. Murali

Hon. President ABLE

Managing Director & CEO, Evolva Biotech


Serial entrepreneur for more than two decades with many first of its kind products and innovations in many areas of biotechnology; Built pioneering IT green field projects. Was part of a Venture capital organization to evaluate prospective technologies for commercialization.

Key highlights

Nurtured & built the entire Indian arm of $100 M Swiss biotech company India's first pioneering public-private partnership to setup country's first Genetic Chemistry Laboratory inside a premier CSIR campus - "Indian Institute of Chemical Technology"

Built the R & D subsidiary for the $ 250 M Indian FMCG group Pioneer in the world to conduct full fledged clinical trials (all 4 phases) with polyherbal formulations for 7 disease indications over two decades.

 Mr. Shrikumar Suryanarayan

Mr. Shrikumar Suryanarayan

Vice-President ABLE

Chairman, Sea6 Energy

Shrikumar is the Chairman and co-founder of Sea6 Energy Pvt. Ltd. He was formerly the President of Research and Development at Biocon Limited, Bangalore India (www.biocon.com) and the Chief Scientific Advisor to the company. He was associated with Biocon for over 25 years.

His other appointments include an Adjunct Professorship at the Department of Biotechnology at the Indian Institute of Technology Madras. He is also a member of Governing & Advisory boards of several institutes and centers promoted by the Department of Biotechnology, Government of India and served as the Chief Executive officer for the Translational Health Sciences Institute at the National Capital Region Biosciences Cluster, Government of India from 2009-2010.

Shrikumar has a Bachelor's degree in Chemical Engineering from Indian Institute of technology, Madras and a Master's degree in Biochemical Engineering from the Indian Institute of technology Delhi. In 2001, he was awarded the Biotechnology Process Development award of the Government of India and in 2009 he received the Distinguished Alumnus Award of the Indian Institute of Technology, Madras.

Dr. Goutam Das

Dr. Goutam Das

General Secretary

Dr. Goutam Das earned his Ph.D. in Biology from Indian Institute of Chemical Biology at Kolkata with a post doctoral training in the USA. He started his career with Astra Research Centre India (ARCI was a wholly owned subsidiary of Astra AB, Sweden, currently AstraZeneca Plc) at Bangalore conducting research programs at Bangalore site for Astra Hassle, Sweden. Following ARCI (1988 - 1994) joined a newly founded start up Syngene Intl Ltd as the first Director (later renamed as Chief Operating Officer) and stayed with the company for seventeen years (1994 - 2010).

Syngene is a wholly owned subsidiary of India's top biopharmaceutical company, Biocon. Since January 2011 have been associated with a number of companies and a "not for profit" international organization as a strategic advisor on a retainer basis.

Mr. Subramani Ramachandrapa

Mr. Subramani Ramachandrapa

Treasurer ABLE

Chairman and Managing Director, Richcore Lifesciences Pvt. Ltd.

Subramani Ramachandrappa (Subbu) is currently the Founder and CEO of Richcore Lifesciences, a PE funded company focused on developing innovative enzyme solutions for Clean-tech and Bio-pharma applications. He is an Engineer and MBA from ISB, Hyderabad - a Joint program with Kellogg and Wharton School of Business.

He also leads the innovation efforts at Richcore, developing novel enzyme applications targeted to conserve food, water, energy and health, and has filed more than 16 patents.

Subbu actively contributes towards entrepreneurship development and innovation as a speaker and mentor in forums across several countries.
He is a recipient of several awards for innovation and entrepreneurship, Including The Emerging Company of the year- Bio-Industrial, from ABLE in the year in 2011

Dr. Dhananjay B. Patankar

Dr. Dhananjay B. Patankar

Vice President – Biologics at Syngene International, Bangalore, India.

Dr. Dhananjay Patankar is Vice President – Biologics at Syngene International in Bangalore. Syngene is a leading contract service provider in India serving the pharma and biotech industry in drug discovery, development and manufacturing.

Previously Dr. Patankar was involved in the biosimilar industry as Chief Operating Officer of Intas Biopharmaceuticals and as Sr Scientist at Wockhardt. In that tenure, he led the development and commercialization of several biosimilar products, and led the development of India’s first biosimilar product to receive marketing authorization in Europe (filgrastim, sold as Grastofil) as well as the world’s first Pegfilgrastim biosimilar.

Dr. Patankar served as Chair of the USP Expert Committee for Medicines Compendium – Biologics (2010-15) and previously served on the Mashelkar Task Force for regulatory pathway for biosimilars in India (2004).

Dr. Patankar is a Chemical Engineer and obtained his bachelors’ degree from the Indian Institute of Technology, Bombay and his Masters’ and PhD from the University of Utah (US) which was followed by a postdoctoral fellowship at Rutgers University (US).

Dr. Raja Mugasimangalam

Dr. Raja Mugasimangalam

Founder and CEO Genotypic technology

Dr. Raja Mugasimangalam (Founder and CEO Genotypic technology, Bangalore India) is a former technocrat turned entrepreneur in the Genomics Business. Since 1998, he has been working in close collaboration with Biotech, Pharma, Agriculture / seed companies and academia helping them apply Sequencing, Bioinformatics and Microarray technologies to real life research projects. Genotypic has become the key player in Genomics in India and has led to creation of over 5 start-ups in the areas of molecular diagnostics.

Raja publishes actively in peer reviewed journals and is a reviewer in Journals like PLOSone and BMC Genomics. He is member of the board of studies in many universities for Genomics, Genome informatics and Bioinformatics and of several professional organizations like ABLE, IACR and Indian Biochemists Association. He spends a considerable time delivering seminars and lectures at colleges and universities and is popularizing the Genomics Hub concept for a wider application of Genomics and Informatics.

Prior to founding Genotypic Technology, he worked at Quark Biotech Inc (USA and Israel) developing methods for constructing Microarrays. He received his BSc in Biochemistry from PSG CAS (Coimbatore- 1986), Masters (1998) in Biotechnology from MKU and PhD (1994) in Biotechnology from Madurai Kamaraj University and worked as postdoctoral Scientist at Weizmann Institute of Science (Human Genome Project), Israel and Sidney Kimmel Cancer Center, San Diego USA. Raja worked at Argonne National lab (Chicago USA) on developing novel methods for DNA sequencing for Human Genome Project. At Genotypic, Raja collaborates with leading researchers, scientific institutions and pharma-biotech companies from all over the world. Genotypic is in the process of expanding into all the NGS sequencing technology platforms and applications with the goal of ameliorating the wetlab and analysis process and using them in optimal combination for biological research in various domains

Raja runs the world’s largest Genomics linkedin Group: Genomics NGS and Microarrays with more than 32,000 followers.

Secretariat & Consultants

Dr. Anil Ram Chauhan

Sr. Advisor Government relations

Ms. Guljit Chaudhry

Sr. Advisor Bio pharma

Narayanan Suresh

Chief Operating Officer

Suresh is an accomplished journalist and was the Group Editor of BioSpectrum, Asia’s first biotechnology published simultaneously from India and Singapore. A masters in Physics from Central University of Hyderabad, Suresh has covered India’s strides in science & technology, first for Times of India from Delhi and for CyberMedia and MM ActivSci-Tech Communications publications from Bangalore over the last three decades. Suresh was also the Group Editor of MIT Technology Review India Editior published for five years from India and anchored its EmTech Conference and selection Young Innovators under 35 for four years in India and Singapore.

For more than a decade, Suresh has championed the cause of India’s biotechnology sector and pioneered the annual ABLE-BioSpectrum Biotech Industry Survey since 2003, showcased the industry’s highlights around the world, built a highly successful media platform to engage the biotech industry across Asia-Paciifc and a communicator of the industry’s work to the student community and the public.

In the current role, Suresh will be striving to expand the footprint of ABLE to reach out to the entire biotech community and push it towards the goal of achieving a $ 100 billion BioEconomy in the country by 2025.

Pavana Praveen

Manager-Operations & Business Development

For any queries, please contact him at pavanapr@ableindia.org.in